UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Médecine et maladies infectieuses, ISSN 0399-077X, 06/2017, Volume 47, Issue 4, pp. S137 - S137
Journal Article
Médecine et maladies infectieuses, ISSN 0399-077X, 06/2016, Volume 46, Issue 4, p. 122
Journal Article
Médecine et maladies infectieuses, ISSN 0399-077X, 06/2016, Volume 46, Issue 4, p. 123
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 11/2016, Volume 119, pp. 1 - 7
TDF (tenofovir disoproxil fumarate) | HBV (hepatitis B virus) | HIV (human immunodeficiency virus) | TAF (tenofovir alafenamide) | TFV (tenofovir) | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | HIV Infections - prevention & control | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Antiviral Agents - therapeutic use | Humans | Tenofovir - administration & dosage | Tenofovir - economics | Antiviral Agents - administration & dosage | Adenine - administration & dosage | Adenine - economics | Adenine - therapeutic use | HIV Infections - drug therapy | Antiviral Agents - economics | Tenofovir | Index Medicus
Journal Article
Néphrologie & thérapeutique, ISSN 1769-7255, 06/2016, Volume 12, Issue 3, p. 179
Journal Article
Antiviral research, ISSN 0166-3542, 08/2016, Volume 132, pp. 50 - 58
Resistance | HIV-1 | Tenofovir alafenamide | Tenofovir diphosphate | Tenofovir disoproxil fumarate | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Virology | Anti-HIV Agents - pharmacology | Cell Line | HIV-1 - drug effects | HIV Infections - virology | Humans | Tenofovir - pharmacology | Drug Resistance, Viral | Reverse Transcriptase Inhibitors - pharmacology | Tenofovir - chemistry | HIV-1 - genetics | Reverse Transcriptase Inhibitors - chemistry | Viral Load | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Anti-HIV Agents - chemistry | Recombination, Genetic | Tenofovir - analogs & derivatives | RNA, Viral | Mutation | Tenofovir | Comparative analysis | Index Medicus
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 2017, Volume 76, Issue 5, pp. 501 - 511
Adherence | HIV prevention | PrEP | MSM | Preexposure prophylaxis | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | HIV Infections - prevention & control | Tenofovir - blood | HIV Infections - epidemiology | Humans | Tenofovir - pharmacology | Los Angeles - epidemiology | Male | Tenofovir - administration & dosage | Pre-Exposure Prophylaxis | Young Adult | Transgender Persons | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage | Adolescent | Biomarkers | Adult | Female | Patient Compliance | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - pharmacology | Intervention | Emtricitabine | Drugs | Homosexuality | Sexually transmitted diseases--STD | Prophylaxis | Sex | Health risks | Preventive medicine | Quantitation | Patient compliance | Adhesion | Seroconversion | Prevention | Tenofovir | Prescription drugs | Men | Transgender persons | Index Medicus | AIDS/HIV
Journal Article
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 07/2018, Volume 156, pp. 163 - 169
Tenofovir | Plasma | Cerebrospinal fluid | Tenofovir alafenamide | Mass spectrometry | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Chemistry, Analytical | Life Sciences & Biomedicine | Science & Technology | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - analysis | HIV Infections - blood | HIV Infections - cerebrospinal fluid | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use | Emtricitabine - therapeutic use | Reproducibility of Results | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Humans | Adenine - analysis | Chromatography, High Pressure Liquid | Anti-HIV Agents - analysis | Tandem Mass Spectrometry | Adenine - therapeutic use | Emtricitabine - analysis | Tenofovir - analogs & derivatives | Quinolones - analysis | Quinolones - therapeutic use | Solid Phase Extraction | Tenofovir - analysis | Cobicistat - analysis | HIV Infections - drug therapy | Cobicistat - therapeutic use | Drug Combinations | Antiviral agents | Ionization | Analysis | Pharmacy | Formic acid | Nitriles | Liquid chromatography | Organic acids | Index Medicus | mass spectrometry | tenofovir alafenamide | plasma | tenofovir | cerebrospinal fluid
Journal Article
Science (American Association for the Advancement of Science), ISSN 0036-8075, 06/2017, Volume 356, Issue 6341, pp. 938 - 945
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | HIV Infections - prevention & control | Antiviral Agents - pharmacology | Bacteria - metabolism | Microbiota - physiology | Humans | Tenofovir - pharmacology | Proteome | Antiviral Agents - metabolism | Biodiversity | Lactobacillus - metabolism | Bacteria - genetics | HIV Infections - microbiology | Bacteria - isolation & purification | Microbiota - genetics | Mass Spectrometry | Tenofovir - analysis | Tenofovir - metabolism | RNA, Ribosomal, 16S - genetics | Adult | Female | South Africa | Vagina - microbiology | Gardnerella - metabolism | Anaerobic bacteria | Medical research | Correlation | Effectiveness | Communities | Mucosa | Clinical trials | Vagina | Pharmacology | Infections | Metabolism | Incidence | Prevention | Tenofovir | Depletion | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Men | Bacteria | Index Medicus | Drugs | Strategy | Human immunodeficiency virus | Medicin och hälsovetenskap
Journal Article
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 11/2016, Volume 131, pp. 146 - 155
MSn | Tenofovir alafenamide fumarate | Prodrug | LC-HRMS | Tenofovir disoproxil fumarate | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Chemistry, Analytical | Life Sciences & Biomedicine | Science & Technology | Anti-Retroviral Agents - chemistry | Prodrugs - analysis | Drug Stability | Humans | Tenofovir - chemistry | Prodrugs - chemistry | Prodrugs - metabolism | Anti-Retroviral Agents - metabolism | Anti-HIV Agents - analysis | Anti-HIV Agents - chemistry | Anti-Retroviral Agents - analysis | Tenofovir - analysis | Tenofovir - metabolism | Anti-HIV Agents - metabolism | Tenofovir | Comparative analysis | Highly active antiretroviral therapy | Drugs | Mass spectrometry | High performance liquid chromatography | Index Medicus
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 04/2016, Volume 62, Issue 7, pp. 915 - 918
cost-effectiveness | costs | tenofovir alafenamide | tenofovir disoproxil fumarate | generics | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Bone Diseases - chemically induced | Anti-HIV Agents - economics | Tenofovir - adverse effects | Tenofovir - therapeutic use | HIV Infections - economics | United States | Anti-HIV Agents - adverse effects | Humans | Tenofovir - economics | Cost-Benefit Analysis | Kidney Diseases - chemically induced | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Tenofovir | Diagnosis | Research | HIV (Viruses) | Antiretroviral drugs | Toxicity | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
Pharmaceutical research, ISSN 0724-8741, 12/2017, Volume 34, Issue 12, pp. 2749 - 2755
Biochemistry, general | tissue distribution profile | nanoformulation | Biomedicine | Pharmacy | elvitegravir | pharmacokinetics | Medical Law | tenofovir alafenamide | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Tenofovir - blood | Nanoparticles - chemistry | Humans | Tenofovir - chemistry | Delayed-Action Preparations - chemistry | Tenofovir - administration & dosage | Tenofovir - pharmacokinetics | Drug Carriers - chemistry | Anti-HIV Agents - administration & dosage | Tissue Distribution | Quinolones - blood | Anti-HIV Agents - chemistry | Quinolones - administration & dosage | Animals | Quinolones - chemistry | Quinolones - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Female | HIV Infections - drug therapy | Mice | Anti-HIV Agents - blood | Tenofovir | Medical colleges | Analysis | CD34 antigen | Drugs | Stress concentration | Prophylaxis | Pharmacology | Exposure | Nanoparticles | Load distribution (forces) | Antiretroviral agents | Rodents | Sustained release | Drug dosages | Controlled release | Index Medicus | Pharmacokinetics
Journal Article
Drug safety, ISSN 0114-5916, 04/2017, Volume 40, Issue 4, pp. 273 - 283
HIV Infections | Tenofovir | Animals | Humans | Anti-HIV Agents | Review | Journal Article | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Pre-Exposure Prophylaxis | Medicine & Public Health | Drug Safety and Pharmacovigilance | Pharmacology/Toxicology | Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Toxicology | Life Sciences & Biomedicine | Science & Technology | Anti-HIV Agents - administration & dosage | HIV Infections - prevention & control | Pre-Exposure Prophylaxis - methods | Tenofovir - adverse effects | Anti-HIV Agents - adverse effects | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage | Tenofovir - administration & dosage | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects | Prevention | Clinical trials | Usage | Drug therapy | HIV infection | Intervention | Renal function | Toxicity | Liver | Prophylaxis | Viruses | Infections | Incidence | Mens health | Hepatitis | Acquired immune deficiency syndrome--AIDS | Vomiting | Human immunodeficiency virus--HIV | Risk assessment | Search engines | Bone density | Safety | Product safety | Drug dosages | Drug use | Monitoring | Emtricitabine | Enzymes | Medical research | Effectiveness | Health risks | Diarrhea | Exposure | Nausea | Pharmacology | Disease control | Disease prevention | Side effects | Disease transmission | Reviews | Bone mineral density | Kidney transplantation | Index Medicus
Journal Article
AIDS (London), ISSN 0269-9370, 07/2016, Volume 30, Issue 12, pp. 1973 - 1983
meta-analysis | HIV prevention | HIV | preexposure prophylaxis | systematic review | tenofovir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | HIV Infections - prevention & control | Pre-Exposure Prophylaxis - methods | Tenofovir - adverse effects | Administration, Oral | Anti-HIV Agents - adverse effects | Humans | Male | Tenofovir - administration & dosage | Anti-HIV Agents - administration & dosage | Chemoprevention - adverse effects | Young Adult | Adult | Female | Placebos - administration & dosage | Chemoprevention - methods | Index Medicus | AIDS/HIV | Epidemiology and Social
Journal Article